Zymeworks Inc. a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The Company operates through a number of platforms, including Azymetric, which is a bispecific platform enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets; ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins, and EFECT, which enables finely tuned modulation (both up and down) of immune cell recruitment and function. Its lead product candidate is ZW25, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). It product candidate ZW49, combines the design of ZW25 with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker.